| Ytd | -10.38% | |
| 1y | -28.69% |
| Open | 7.05 | Prev Close | 7.93 | Low | 7.05 | High | 8.09 | Mkt Cap | 52.84M |
| Vol | 7.91K | Avg Vol | 12.46K | EPS | -0.60 | P/E | N/A | Forward P/E | -1.91 |
| Beta | -0.20 | Short Ratio | 0.42 | Inst. Own | 29.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.83 | 200-d Avg | 8.50 | 1yr Est | 4.50 |
XLO News
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and devel
XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbo
Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with
WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical
Dr. Houvras brings over two decades of executive leadership across premier industry and academic res
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / ma
WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.58 per share versus the Zacks Co
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 fo
WALTHAM, Mass. , May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical
XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost ou
XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission
WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
Playboy (PLBY) shares rise in pre-market trading after reporting better-than-expected Q4 results. Ot
WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the comp